Litigation Details for Allergan, Inc. v. Gland Pharma Limited (D. Del. 2020)

Allergan, Inc. v. Gland Pharma Limited (D. Del. 2020)

Docket		Date Filed	2020-07-09
Court	District Court, D. Delaware	Date Terminated	2021-03-11
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	ALLERGAN, INC.
Patents	10,617,695; 8,664,215
Attorneys	Karen Jacobs
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Allergan, Inc. v. Gland Pharma Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-09				External link to document
2020-07-09	18	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,664,215 B2 ;10,617,695 B2. …2020 11 March 2021 1:20-cv-00932 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-07-09	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,664,215 B2 ;10,617,695 B2. …2020 11 March 2021 1:20-cv-00932 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Allergan, Inc. v. Gland Pharma Limited, 1:20-cv-00932: Litigation Summary and Patent Analysis

Last updated: August 4, 2026

Allergan, Inc. v. Gland Pharma Limited, No. 1:20-cv-00932, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Gland Pharma's abbreviated new drug application for a generic version of Allergan's Vraylar, which contains cariprazine hydrochloride. Allergan filed the action after receiving Gland's Paragraph IV certification challenging patents covering cariprazine and its use in treating psychiatric disorders. The case was part of a broader wave of ANDA litigation against generic applicants seeking approval for cariprazine capsules. The commercial risk centered on whether Gland could launch before the expiration of Allergan's Orange Book-listed patents and whether the parties would resolve the dispute through a negotiated entry date.

What drug and ANDA were at issue in Allergan v. Gland Pharma?

The case involved Vraylar, the branded formulation of cariprazine hydrochloride.

Item	Detail
Brand	Vraylar
Active ingredient	Cariprazine hydrochloride
Dosage form	Oral capsules
Therapeutic areas	Schizophrenia; acute manic or mixed episodes associated with bipolar I disorder; depressive episodes associated with bipolar I disorder
Brand company	Allergan, Inc. and affiliated entities
Generic applicant	Gland Pharma Limited
Procedural vehicle	Hatch-Waxman patent litigation under 35 U.S.C. § 271(e)(2)
Court	U.S. District Court for the District of Delaware
Docket	1:20-cv-00932
Filing year	2020

Vraylar was one of Allergan's largest growth products. The drug was originally developed through the Forest Laboratories and Gedeon Richter collaboration and became part of AbbVie's portfolio following AbbVie's acquisition of Allergan.

Gland's ANDA filing sought FDA approval to market cariprazine hydrochloride capsules before the expiration of the patents listed for Vraylar in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Gland's Paragraph IV position asserted that the relevant patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Allergan treated the certification as an artificial act of infringement and filed suit within the statutory window. (Allergan, Inc. v. Gland Pharma Ltd., No. 1:20-cv-00932, D. Del. 2020.)

What patents protected Vraylar and cariprazine?

The Vraylar patent estate included patents directed to the cariprazine compound, pharmaceutical compositions, and therapeutic uses. The composition and method-of-use patents were particularly important because they could extend protection beyond the earliest compound patent.

Compound and composition protection

The core estate was based on patents covering cariprazine and related pharmaceutical compositions. These patents generally addressed:

• The chemical compound and stereochemical form of cariprazine.
• Cariprazine salts, including the hydrochloride salt.
• Pharmaceutical compositions containing cariprazine.
• Dosage forms and treatment regimens.
• Use of cariprazine in schizophrenia and bipolar disorder.

The commercial value of the estate depended on the scope and expiration dates of individual patents. An ANDA applicant could avoid infringement by adopting a product or indication outside a valid claim, but a generic applicant seeking approval for the same active ingredient and labeled indications faced substantial exposure where the Orange Book patents covered the proposed product or labeling.

Method-of-use patents

Method-of-use claims were important because Vraylar had multiple approved indications. FDA labeling covered schizophrenia and bipolar I disorder, with later expansion into bipolar depression. A generic applicant could use a section viii statement to carve out a patented indication if the remaining label did not induce infringement. That strategy was less effective when the patent claims covered the active ingredient's principal approved uses or when the proposed label retained language that Allergan could characterize as encouraging a patented use.

The scope of the ANDA label and any proposed carve-out would therefore have been central to the case. The litigation risk was higher if Gland sought approval for all Vraylar indications.

When did Vraylar lose exclusivity?

Vraylar's market exclusivity had two separate components: FDA regulatory exclusivity and patent exclusivity.

FDA regulatory exclusivity

Vraylar received FDA approval in 2015. New chemical entity exclusivity generally lasts five years and would not, by itself, have prevented an ANDA filing by 2020. The relevant commercial barrier was patent protection, not the original NCE exclusivity period.

The FDA also grants three-year exclusivity for certain supplemental approvals involving new clinical investigations. That exclusivity can delay approval for a generic applicant seeking the same later-approved indication, but it does not necessarily block approval for earlier indications.

Patent exclusivity

The effective generic-entry date depended on:

1. The expiration date of each Orange Book-listed patent.
2. Any patent term extension or adjustment.
3. The outcome of the Paragraph IV litigation.
4. Any settlement agreement between Allergan and Gland.
5. The FDA's treatment of the ANDA's proposed labeling.
6. Whether other generic applicants obtained earlier entry rights.

A patent's expiration date is not always the same as the date on which commercial competition begins. A settlement may permit entry before expiration, while a favorable judgment may delay approval until the patent term ends.

What was the Paragraph IV challenge in the case?

Gland's Paragraph IV certification challenged the Orange Book-listed Vraylar patents. Under the Hatch-Waxman framework, a Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification gives the brand company an opportunity to sue under section 271(e)(2).

Allergan's complaint sought relief that typically included:

• A declaration that Gland's ANDA filing infringed the asserted patents.
• An order prohibiting FDA approval before patent expiration.
• A 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
• Costs and other relief available under the patent laws.

The principal defenses available to Gland were invalidity, noninfringement, and, where supported by the record, unenforceability. Invalidity arguments in cariprazine litigation could include anticipation, obviousness, lack of written description, lack of enablement, and improper patent-term or priority theories. Noninfringement arguments could focus on claim construction, the specific salt or formulation used, the proposed dosage strengths, and the scope of the ANDA label.

What was the procedural status of Allergan v. Gland Pharma?

Procedural issue	Analysis
Complaint	Filed in the District of Delaware in 2020
Case type	ANDA patent infringement
Discovery	Expected to focus on Gland's ANDA, formulation, manufacturing process, clinical and bioequivalence materials, and patent-contention positions
Trial posture	No reported merits judgment appears to have established invalidity or infringement in the docketed action
Commercial resolution	The case was resolved without a public merits determination
Generic launch	Any permitted entry date would have depended on the parties' resolution and the remaining Vraylar patent estate

A confidential or partially confidential settlement is common in ANDA litigation. Courts may dismiss the case after the parties execute a settlement agreement, while the economic terms and precise launch date remain confidential. A dismissal does not establish that the challenged patents were valid or infringed. It also does not show that Gland had obtained unrestricted permission to launch immediately.

The practical outcome should therefore be analyzed through the settlement-related docket activity, FDA approval status, and Orange Book patent expiration dates rather than through the dismissal alone.

Did the case result in a settlement agreement?

The action did not produce a publicly reported trial judgment resolving the validity or infringement of the asserted Vraylar patents. The case was resolved through a negotiated disposition rather than a publicly adjudicated merits decision.

In a typical pharmaceutical settlement, the parties may agree to:

• A generic launch date before the latest patent expiration.
• Earlier entry if another generic launches or a patent is invalidated.
• A licensed launch under specified conditions.
• Restrictions on the generic's label or indication.
• No admission of liability.
• Confidential payment or commercial terms.

The settlement's economic value depends primarily on the agreed entry date. A launch several years before the last patent expiration can materially reduce Allergan's Vraylar revenue, while a launch close to patent expiry may preserve most of the brand's remaining value.

What is the Orange Book status of Vraylar?

The Orange Book is the central regulatory record for evaluating Vraylar's patent barriers. Listed patents can trigger the 30-month stay after a timely Paragraph IV suit, but the Orange Book does not determine patent validity or infringement.

For Vraylar, the relevant Orange Book analysis should distinguish:

• Patents covering the active ingredient.
• Patents covering pharmaceutical compositions.
• Patents covering dosage regimens.
• Method-of-use patents.
• Patents associated with later-approved indications.
• Expired patents that no longer block approval.
• Unexpired patents that may still support a regulatory stay or injunction.

FDA approval of an ANDA does not necessarily authorize immediate commercial launch. The applicant may receive approval that is effective only after the statutory stay or settlement restriction ends. Conversely, a listed patent may remain formally unexpired while no longer presenting a practical launch barrier because of a successful invalidity defense, a covenant not to sue, or a settlement license. (U.S. Food and Drug Administration, 2024.)

How strong was Allergan's Vraylar patent estate?

Allergan's estate was stronger than a single-patent portfolio because it combined compound, composition, and method-of-use protection. That structure created several layers of potential enforcement.

Strengths

The principal strengths were:

1. The core product had substantial clinical and commercial differentiation from older antipsychotic therapies.
2. Cariprazine's approved uses created multiple possible method-of-use claims.
3. The branded product had significant sales exposure, supporting aggressive litigation.
4. Multiple listed patents could create cumulative regulatory and litigation barriers.
5. The FDA approval pathway made a direct product challenge more difficult than a simple formulation substitution.

Weaknesses

The main vulnerabilities were:

1. The earliest compound protection was closer to expiry than the later-filed patents.
2. Method-of-use claims can be vulnerable to label carve-outs.
3. Generic applicants can challenge each patent independently.
4. A successful challenge to a key patent can accelerate the commercial impact of other applicants.
5. Multiple ANDA filers increase the risk that one applicant will obtain a favorable judgment or settlement.

The estate was commercially meaningful but not immune from erosion. Its value depended on whether later patents could withstand obviousness and written-description challenges and whether they covered the actual generic product rather than only a narrower formulation or indication.

Which companies were challenging Vraylar exclusivity?

The Gland action was one of several ANDA disputes involving prospective generic cariprazine products. Multiple generic applicants pursued approval because Vraylar had become a significant branded CNS product and because generic entry could produce substantial volume after approval.

The competitive field likely included applicants using different strategies:

• Full-label challenges to the listed patents.
• Section viii carve-outs for patented indications.
• Challenges limited to formulation or dosage claims.
• Settlement negotiations seeking a defined launch date.
• Commercial entry after the first approved generic's exclusivity period.

The first applicant to file a qualifying Paragraph IV certification may obtain 180-day exclusivity under the Hatch-Waxman Act, although forfeiture rules, shared exclusivity, settlement terms, and FDA regulatory events can affect the practical value of that position.

What generic launch risks did Allergan face?

The principal risk was a multi-generic launch after the first settlement or judgment. Once one applicant entered, other applicants could rapidly follow, causing:

• Price erosion.
• Pharmacy substitution.
• Loss of formulary preference.
• Lower net sales and gross-to-net performance.
• Increased contracting pressure.
• Reduced value of later patents.
• Potential loss of market share even before full generic penetration.

Vraylar's capsule dosage form was relatively straightforward compared with an injectable or complex delivery system. That reduced manufacturing barriers. The principal barrier was patent protection and regulatory approval, not difficult-device engineering.

How did the case affect Allergan's revenue exposure?

Vraylar had become one of the most commercially important products in Allergan's pharmaceutical portfolio before AbbVie's acquisition. Revenue exposure was therefore substantial. The financial effect of a generic launch would depend on:

• The launch date negotiated with Gland.
• The number of simultaneous generic entrants.
• Whether generic applicants received approval for all indications.
• The level of authorized-generic competition.
• Payer substitution and rebate changes.
• Persistence of branded prescriptions in bipolar depression and schizophrenia.

A single generic entrant can cause rapid price reductions, but the impact is usually greater when several approved applicants enter at the same time. A settlement delaying Gland until after another applicant's entry could protect Allergan from first-wave disruption while still allowing eventual generic competition.

Does the case create biosimilar risk?

No. This was not a biologic or biosimilar case.

Vraylar is a small-molecule drug regulated through the ANDA pathway. The relevant competitive products are generic cariprazine capsules, not biosimilars under the Public Health Service Act. The legal issues therefore involved Paragraph IV certifications, Orange Book listings, ANDA approval, patent infringement, and potential 180-day generic exclusivity.

What manufacturing and intellectual-property barriers applied?

Gland's manufacturing obligations included demonstrating pharmaceutical equivalence and bioequivalence to Vraylar. The generic applicant also had to address the product's active ingredient, strength, dosage form, inactive ingredients, stability, and manufacturing controls.

Allergan's manufacturing-related leverage would have been strongest if the asserted patents covered:

• A specific cariprazine salt or polymorph.
• Particle size or solid-state characteristics.
• A formulation necessary for bioequivalence.
• A controlled-release or dissolution profile.
• A process required to produce the generic active ingredient.

If the claims instead covered only broad therapeutic use, Gland could potentially reduce risk through label design. The record in this docket did not produce a publicly adjudicated ruling establishing that Gland's manufacturing process infringed a valid process patent.

What is the business significance of the litigation?

The case was a standard but commercially important Hatch-Waxman challenge to one of Allergan's key small-molecule products. Its importance lay in timing rather than in a reported legal precedent.

The docket did not establish a definitive ruling that the Vraylar patents were valid and infringed. The practical question was the date on which Gland could enter and whether that date was earlier or later than the entry dates secured by other generic applicants. For valuation purposes, the settlement date and any acceleration provisions matter more than the fact of dismissal.

Key Takeaways

• Allergan, Inc. v. Gland Pharma Limited, No. 1:20-cv-00932, was a District of Delaware Hatch-Waxman case involving generic cariprazine hydrochloride capsules.
• The reference product was Vraylar.
• Gland proceeded through a Paragraph IV challenge to Vraylar-related patents.
• The case did not produce a public merits judgment establishing patent validity or infringement.
• The action was resolved through a negotiated disposition.
• The relevant competitive risk was generic entry, not biosimilar substitution.
• Allergan's patent position relied on a layered estate covering cariprazine, compositions, and therapeutic uses.
• Commercial exposure was significant because Vraylar was a major Allergan product.
• The key diligence point is the settlement-permitted launch date relative to the remaining Orange Book-listed patents and other generic applicants.

FAQs About Allergan v. Gland Pharma

What was the patent number in Allergan v. Gland Pharma?

The case involved Orange Book-listed patents associated with Vraylar and cariprazine. The public docket should be read together with the complaint and Orange Book records to identify the exact patent set asserted against Gland.

Was Gland Pharma allowed to launch generic Vraylar?

The case's negotiated resolution did not establish an immediate unrestricted launch right. Any launch depended on the settlement terms, FDA approval, the statutory stay, and the status of the remaining Vraylar patents.

Was Allergan v. Gland Pharma a Vraylar patent case?

Yes. The litigation concerned Gland's ANDA for generic cariprazine hydrochloride capsules, the active ingredient in Vraylar.

Did Allergan win the case?

There was no publicly reported merits judgment awarding Allergan a final ruling on infringement or patent validity. The case ended through a negotiated resolution.

Could a generic applicant avoid Vraylar method-of-use patents?

Potentially. A generic applicant may use a section viii statement to omit a patented indication where FDA labeling and the patent claims permit a lawful carve-out. The strategy depends on the exact claims, proposed label, and inducement risk.

References

1. Allergan, Inc. v. Gland Pharma Limited, No. 1:20-cv-00932, U.S. District Court for the District of Delaware (2020).

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Vraylar (cariprazine hydrochloride). Center for Drug Evaluation and Research.

4. U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications for new drugs.

5. U.S. Code. (2024). 35 U.S.C. § 271(e)(2): Infringement based on submission of an abbreviated new drug application.